+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Addison's Disease Treatment Market by Drug Class (Glucocorticoid, Mineralocorticoid), Diagnosis (Imaging Testing, Laboratory Testing), Treatments, Distribution Channel, Route of Administration - Forecast 2024-2030

  • PDF Icon

    Report

  • 195 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5716017
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Addison's Disease Treatment Market size was estimated at USD 1.41 billion in 2023, USD 1.54 billion in 2024, and is expected to grow at a CAGR of 10.72% to reach USD 2.88 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Addison's Disease Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Addison's Disease Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Addison's Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Actiza Pharmaceutical Private Limited, Akorn Operating Company LLC, Amgen Inc., Amneal Pharmaceuticals, Inc., Bay Biosciences LLC, Bayer AG, Bio-Techne Corporation, Biogen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, BTL Biotechno Labs Pvt Ltd., Cardinal Health, Inc., Eli Lilly and Company, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, LUMITOS AG, Lupin Limited, Merck KGaA, Neurocrine Biosciences, Inc., Novartis AG, Pfizer Inc., Recipharm AB, Sandoz International GmbH, and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Addison's Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Class
    • Glucocorticoid
      • Dexamethasone
      • Hydrocortisone
      • Prednisone
    • Mineralocorticoid
      • Fludrocortisone
  • Diagnosis
    • Imaging Testing
    • Laboratory Testing
  • Treatments
    • Corticosteroid Injections
    • Naturopathic Solutions
    • Oral Corticosteroids
  • Distribution Channel
    • E-Commerce
    • Hospital Pharmacy
    • Retail Pharmacy
  • Route of Administration
    • Oral
    • Parental
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Addison's Disease Treatment Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Addison's Disease Treatment Market?
  3. What are the technology trends and regulatory frameworks in the Addison's Disease Treatment Market?
  4. What is the market share of the leading vendors in the Addison's Disease Treatment Market?
  5. Which modes and strategic moves are suitable for entering the Addison's Disease Treatment Market?

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Purchase of this report includes 1 year online access with quarterly updates

Purchase of this report includes 1 year online access with quarterly updates

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Addison's Disease Treatment Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidences of Addison's disease globally
5.1.1.2. Growing awareness regarding adrenal insufficiency
5.1.1.3. Inception of robust healthcare infrastructure and favorable reimbursement policies
5.1.2. Restraints
5.1.2.1. High costs associated with the Addison treatment medications
5.1.3. Opportunities
5.1.3.1. Growing demand for new generation technologically integrated advanced therapeutic drugs
5.1.3.2. Increasing R&D activities and rising focus of the companies in developing treatments for Addison's disease
5.1.4. Challenges
5.1.4.1. Lack of awareness among people regarding Addison's disease
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Addison's Disease Treatment Market, by Drug Class
6.1. Introduction
6.2. Glucocorticoid
6.3.1. Dexamethasone
6.3.2. Hydrocortisone
6.3.3. Prednisone
6.3. Mineralocorticoid
6.4.1. Fludrocortisone
7. Addison's Disease Treatment Market, by Diagnosis
7.1. Introduction
7.2. Imaging Testing
7.3. Laboratory Testing
8. Addison's Disease Treatment Market, by Treatments
8.1. Introduction
8.2. Corticosteroid Injections
8.3. Naturopathic Solutions
8.4. Oral Corticosteroids
9. Addison's Disease Treatment Market, by Distribution Channel
9.1. Introduction
9.2. E-Commerce
9.3. Hospital Pharmacy
9.4. Retail Pharmacy
10. Addison's Disease Treatment Market, by Route of Administration
10.1. Introduction
10.2. Oral
10.3. Parental
11. Americas Addison's Disease Treatment Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Addison's Disease Treatment Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Addison's Disease Treatment Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. Abbott Laboratories
15.1.2. Actiza Pharmaceutical Private Limited
15.1.3. Akorn Operating Company LLC
15.1.4. Amgen Inc.
15.1.5. Amneal Pharmaceuticals, Inc.
15.1.6. Bay Biosciences LLC
15.1.7. Bayer AG
15.1.8. Bio-Techne Corporation
15.1.9. Biogen Inc.
15.1.10. Boehringer Ingelheim International GmbH
15.1.11. Bristol-Myers Squibb Company
15.1.12. BTL Biotechno Labs Pvt Ltd.
15.1.13. Cardinal Health, Inc.
15.1.14. Eli Lilly and Company
15.1.15. GlaxoSmithKline PLC
15.1.16. Hikma Pharmaceuticals PLC
15.1.17. LUMITOS AG
15.1.18. Lupin Limited
15.1.19. Merck KGaA
15.1.20. Neurocrine Biosciences, Inc.
15.1.21. Novartis AG
15.1.22. Pfizer Inc.
15.1.23. Recipharm AB
15.1.24. Sandoz International GmbH
15.1.25. Takeda Pharmaceutical Company Limited
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing
List of Figures
FIGURE 1. ADDISON'S DISEASE TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. ADDISON'S DISEASE TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. ADDISON'S DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. ADDISON'S DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. ADDISON'S DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ADDISON'S DISEASE TREATMENT MARKET DYNAMICS
FIGURE 7. ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 8. ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
FIGURE 10. ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2023 VS 2030 (%)
FIGURE 12. ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 14. ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 16. ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. ADDISON'S DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 26. ADDISON'S DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • Actiza Pharmaceutical Private Limited
  • Akorn Operating Company LLC
  • Amgen Inc.
  • Amneal Pharmaceuticals, Inc.
  • Bay Biosciences LLC
  • Bayer AG
  • Bio-Techne Corporation
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • BTL Biotechno Labs Pvt Ltd.
  • Cardinal Health, Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • LUMITOS AG
  • Lupin Limited
  • Merck KGaA
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Recipharm AB
  • Sandoz International GmbH
  • Takeda Pharmaceutical Company Limited

Methodology

Loading
LOADING...

Table Information